E-health-supported Diagnostic and Intervention in Preterm Born Children and Their Families
Launched by UNIVERSITY HOSPITAL TUEBINGEN · Apr 14, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to support families with premature babies, specifically those born between 28 and 34 weeks of pregnancy. The researchers want to see if an app can help identify mental and physical health needs in these children and their families, aiming to improve care after they leave the hospital. Families will be divided into two groups: one that will use the app and another that will receive standard care.
To participate, mothers must be at least 18 years old, have internet access, and be able to communicate in German. Unfortunately, families with babies born before 28 weeks or after 34 weeks, or those with serious health issues, won't be eligible. If you join the study, you can expect support through the app, which focuses on strengthening your family's well-being during a challenging time. The trial is currently recruiting participants, and your involvement could contribute to better care for future families with premature babies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Premature babies born at the UKT,
- • Gestational age 28-34 weeks,
- • Mother: age ≥ 18 years,
- • agreement to participate in this study and signing of a consent form,
- • sufficient knowledge of German,
- • internet access
- Exclusion Criteria:
- • Premature babies \< 28th or \>34th week of pregnancy,
- • at least one of the children has serious diseases of the nervous system or obvious symptoms of a nervous disease,
- • at least one of the children has serious congenital diseases or suffers from malformations,
- • Mother: Lack of access to a smartphone/tablet,
- • no internet access,
- • insufficient knowledge of German
About University Hospital Tuebingen
University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tuebingen, , Germany
Tuebingen, Baden Württemberg, Germany
Patients applied
Trial Officials
Annette Conzelmann, Prof. Dr.
Principal Investigator
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Tübingen
Annika K Alt
Study Chair
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Tübingen
Tobias J Renner, Prof. Dr.
Principal Investigator
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Tübingen
Axel Franz, Prof. Dr.
Study Chair
Neonatology, University of Tübingen
Mirja Quante, Dr.
Study Chair
Neonatology, University of Tübingen
Michaela Minarski, Dr.
Study Chair
Neonatology, University of Tübingen
Johanna Löchner, Prof. Dr.
Study Chair
Clinical Psychology, FAU Erlangen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported